Roundtable on Black in cancer research and oncology - presented by Dr. Brandon Blue MD and Dr. Kilan Ashad-Bishop and Drs. Onyinye and Folu Balogun and Runcie C.W. Chidebe Dip., BSc., MSc., and Kathryn Mcginnis and Dr Paraskevi Mallini and Dr. Lisa Hoffmann-Haas

Roundtable on Black in cancer research and oncology

Brandon Blue, Kilan Ashad-Bishop, Onyinye and Folu Balogun and Runcie C.W. Chidebe

Dr. Brandon Blue MDDr. Kilan Ashad-BishopDrs. Onyinye and Folu BalogunRuncie C.W. Chidebe Dip., BSc., MSc.,
Slide at 06:48
Affordability and access
Dr. Brandon Blue
Evaluation of socioeconomic data is ongoing, but are we
reaching the patients in our catchment area with CAR T?
FY18: Moffitt all new
Race and Ethnicity of
DLBCL patients (n=410)
Diffuse Large B cell
FY15-18: Moffitt DLBCL
CAR-T patients (n=77)
Lymphoma patients at
Moffitt Cancer Center
African
Share slide
Summary (AI generated)

And so, what we were able to see is that the access to these new therapies for people unfortunately created an issue, as it was not standardized across the board. Not everyone who had this new emerging novel way of treating cancer had access to it. Unfortunately, this is something we are trying to change.

To evaluate this, one of the things we did that we are very proud of is sending questionnaires to some oncologists here in the State of Florida. We asked them if they send people to Cart, and if not, why not. Through our research, we found that doctors who were less likely to understand Cart and how to take care of Cart were also less likely to send people for it.

It is important for people to know that once they come to us for Cart, they don't stay as a Cart patient. They do go back to their community, and their local doctor is typically able to take care of them.